Telomir says Telomir-Zn restores visual function, retinal structure in AMD preclinical model

Telomir Pharmaceuticals highlighted a peer-reviewed preclinical study showing Telomir-Zn improved visual function in a zebrafish AMD model.

Oral dosing for 14 days restored retinal structure, improved visual response, and reduced oxidative stress linked to mitochondrial dysfunction.

Mechanistic work tied the effects to lower labile iron, higher intracellular zinc, and inhibition of iron-dependent histone demethylases; KDM5B IC50 was 63 nM.

Relative telomeric DNA content increased dose-dependently toward healthy profiles, and selected aging-linked DNA methylation changes shifted toward normal.

Clinical development remains centered on oncology; Telomir-Zn is under an FDA-cleared IND for a Phase 1/2 TNBC trial.